Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI hunts for early clues to Parkinson's and Alzheimer's progression

NCT ID NCT06596746

Knowledge-focused Sponsor: Casa di Cura San Raffaele Cassino Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 02, 2026 · Last updated Sep 03, 2026 · Updated 1 time

Summary

This study follows 600 people with neurodegenerative diseases such as Parkinson's, Alzheimer's, and related conditions over 1 to 10 years. Researchers collect data from routine clinical exams, brain imaging, movement analysis, and blood tests. They use statistical tools and artificial intelligence to search for markers that could predict how these diseases progress and help with early diagnosis.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could identify early warning signs of neurodegenerative diseases, helping doctors diagnose and predict their course sooner.
What could go wrong
This is an observational study, not a treatment test. It may not produce clear markers, and findings from this group may not apply to everyone with these diseases.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 600 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2024

Expected to finish

Sep 2034

An estimate. End dates often move.

Lead sponsor

A research network

The lead sponsor is a research network or cooperative group.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with Neurodegerative Diseases

Ages

10 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with diagnosis of Parkinson's Disease, Parkinsonism and Movement Disorders * Patients with diagnosis of Parkinson's Disease * Diagnosis of Parkinson's Disease according to the United Kingdom (UK) Parkinson's Disease Society Brain Bank * Diagnosis of Movement Disorder not related to Parkinson's Disease * Diagnosis of Multiple System Atrophy (MSA) in accordance with Second Consensus Statement on Diagnosis of Multiple System Atrophy; * Diagnosis of Progressive Supranuclear Palsy according to Movement Disorder Society for Diagnosis of Progressive Supranuclear Palsy; * Diagnosis of Essential Tremor * Willing to participate in the study, understand the procedures and sign the informed consent. * Patients affected by cognitive impairment (CI) and dementia * Diagnosis of probable: * Lewy Body Dementia * Alzheimer's Disease * Mild Cognitive Decline * Subjective memory complaints * Willing to participate in the study, understand the procedures and sign the informed consent. Exclusion Criteria: * There are no restrictions for participation in the study based on age, severity of illness or presence of cognitive impairment, as long as the person is able to complete the research assessments.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alzheimer disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease amyotrophic lateral sclerosis Cognitive Dysfunction Corticobasal Degeneration corticobasal degeneration disorder dementia essential tremor frontotemporal dementia Frontotemporal Lobar Degeneration Iron Overload iron poisoning Lewy body dementia Lewy Body Disease movement disorder multiple system atrophy neurodegeneration with brain iron accumulation neurodegenerative disease pantothenate kinase-associated neurodegeneration Parkinson disease progressive supranuclear palsy subjective cognitive decline supranuclear palsy, progressive, 1 synucleinopathy tauopathy TDP-43 proteinopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alzheimer disease Amyotrophic lateral sclerosis Atypical parkinsonism Cognitive impairment Corticobasal degeneration Dementia Frontotemporal lobar degeneration Iron overload Lewy body disease Movement disorders Multiple system atrophy Neurodegeneration with brain iron accumulation (NBIA) Neurodegenerative diseases Parkinson disease Supranuclear palsy, progressive Synucleinopathies Tauopathies TDP-43 proteinopathies

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • San Raffaele Cassino

    RECRUITING

    Cassino, Frosinone, 03043, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.